24 patients with HbA1c of 8% or higher
Reduces the time for high blood sugar and does not increase the time for hypoglycemia
A study has found that automatic insulin administration (AID, artificial pancreas) is safe and effective for type 2 diabetes.
Dr. Georgia Davis of Emory University in the US verified the effectiveness and safety of an artificial pancreas for patients with type 2 diabetes and published it in Diabetes Care.
According to the doctor, there are many diabetic patients who need insulin injection, but automatic insulin administration was mainly for type 1 diabetes.
AID, which appeared in the midst of this, automatically administers the amount of insulin appropriate to the blood sugar level measured in real time with a glucose monitor device. In the United States, Omnipot 5 was approved last year, but its safety and effectiveness in patients with type 2 diabetes have not been sufficiently verified.
The subjects of this study were 24 type 2 diabetic patients (average age 60.6 years) with HbA1c of 8-12% (average 9.4%) while receiving insulin treatment. Patients with a history of severe hypoglycemia within the past 6 months, regardless of whether or not they were using a glucose monitor, were excluded.
The subjects were diagnosed with diabetes for an average of 19 years, the average body mass index (BMI) was 33.5, 50% were female, the average daily insulin dose was 61.5 units, and the number of additional short-acting insulin doses was 1.6 times.
The subjects were divided into 12 basic/additional groups and 12 basic groups by insulin therapy pattern, and blood glucose levels were measured during standard treatment for 2 weeks. After using the Omnipod 5 for 8 weeks, the safety and effectiveness were reviewed. Whether or not to continue to use oral diabetes treatment was left to the judgment of the attending physician.
The safety evaluation criterion was determined as the percentage of time when the glucose level reached 250 mg/dL or higher and 54 mg/dL during the period of AID use.
As a result of the review, the rate of time to reach a blood glucose level of 250 mg/dL or higher was 10.5% in the whole group, 9.3% in the basic/additional group, and 11.7% in the basic group. The amount of change compared to the standard treatment period was -16.9%, -12.2%, and -21.6%, all significantly decreased.
Meanwhile, the rate of time to reach 54mg/dL was 0.03% in the basic/additional group and 0% in the total and basic groups, and there was no difference compared to the standard treatment period.
In the evaluation of the effect, the change in HbA1c after the use of AID was determined. As a result, the change in HbA1c decreased significantly by -1.3% in the entire group, -1.2% in the basic/additional group, and -1.4% in the basic group.
In addition, the change in the rate of time when the blood glucose level was within the therapeutic range of 70 to 180 mg/dL was 21.9%, 17.8%, and 26.1%, respectively, all significantly increased.
Dr. Davis concluded, “The effectiveness and safety of OmniPod 5 were confirmed regardless of the insulin administration pattern in type 2 diabetes patients undergoing outpatient treatment.”
He also added, “Additional verification is needed for type 2 diabetic patients who are not getting satisfactory results with current insulin therapy.”
© Medical Tribune Unauthorized reproduction and redistribution prohibited